vs

Side-by-side financial comparison of ASSEMBLY BIOSCIENCES, INC. (ASMB) and Linde plc (LIN). Click either name above to swap in a different company.

ASSEMBLY BIOSCIENCES, INC. is the larger business by last-quarter revenue ($10.8M vs $8.8M, roughly 1.2× Linde plc). On growth, ASSEMBLY BIOSCIENCES, INC. posted the faster year-over-year revenue change (57.6% vs 8.2%). Linde plc produced more free cash flow last quarter ($898.0K vs $-15.2M).

Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.

Linde is a global multinational chemical company and the world's largest industrial gas supplier by market share and revenue. Founded by German scientist and engineer Carl von Linde in 1879 in Wiesbaden, Germany, the company is now headquartered in Woking, United Kingdom, and registered in Ireland as Linde plc. Linde plc was formed in 2018 through the merger of Linde AG and Praxair, which was founded in 1907 in the United States as Linde Air Products Company.

ASMB vs LIN — Head-to-Head

Bigger by revenue
ASMB
ASMB
1.2× larger
ASMB
$10.8M
$8.8M
LIN
Growing faster (revenue YoY)
ASMB
ASMB
+49.4% gap
ASMB
57.6%
8.2%
LIN
More free cash flow
LIN
LIN
$16.1M more FCF
LIN
$898.0K
$-15.2M
ASMB

Income Statement — Q3 FY2025 vs Q1 FY2026

Metric
ASMB
ASMB
LIN
LIN
Revenue
$10.8M
$8.8M
Net Profit
$-9.2M
Gross Margin
48.5%
Operating Margin
-100.9%
27.8%
Net Margin
-85.2%
Revenue YoY
57.6%
8.2%
Net Profit YoY
4.3%
EPS (diluted)
$-0.72
$3.98

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASMB
ASMB
LIN
LIN
Q1 26
$8.8M
Q4 25
$8.8B
Q3 25
$10.8M
$8.6B
Q2 25
$9.6M
$8.5B
Q1 25
$9.4M
$8.1B
Q4 24
$7.4M
$8.3B
Q3 24
$6.8M
$8.4B
Q2 24
$8.5M
$8.3B
Net Profit
ASMB
ASMB
LIN
LIN
Q1 26
Q4 25
$1.5B
Q3 25
$-9.2M
$1.9B
Q2 25
$-10.2M
$1.8B
Q1 25
$-8.8M
$1.7B
Q4 24
$1.7B
Q3 24
$-9.6M
$1.6B
Q2 24
$-11.2M
$1.7B
Gross Margin
ASMB
ASMB
LIN
LIN
Q1 26
48.5%
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Operating Margin
ASMB
ASMB
LIN
LIN
Q1 26
27.8%
Q4 25
23.0%
Q3 25
-100.9%
27.5%
Q2 25
-115.2%
27.7%
Q1 25
-105.5%
26.9%
Q4 24
27.4%
Q3 24
-160.1%
25.0%
Q2 24
-143.0%
26.4%
Net Margin
ASMB
ASMB
LIN
LIN
Q1 26
Q4 25
17.5%
Q3 25
-85.2%
22.4%
Q2 25
-105.9%
20.8%
Q1 25
-93.6%
20.6%
Q4 24
20.8%
Q3 24
-140.4%
18.5%
Q2 24
-130.7%
20.1%
EPS (diluted)
ASMB
ASMB
LIN
LIN
Q1 26
$3.98
Q4 25
$3.28
Q3 25
$-0.72
$4.09
Q2 25
$-1.33
$3.73
Q1 25
$-1.17
$3.51
Q4 24
$3.61
Q3 24
$-1.51
$3.22
Q2 24
$-1.98
$3.44

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASMB
ASMB
LIN
LIN
Cash + ST InvestmentsLiquidity on hand
$22.5M
$4.0M
Total DebtLower is stronger
$24.7M
Stockholders' EquityBook value
$182.7M
$40.1M
Total Assets
$240.0M
$86.3M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASMB
ASMB
LIN
LIN
Q1 26
$4.0M
Q4 25
$5.1B
Q3 25
$22.5M
$4.5B
Q2 25
$24.0M
$4.8B
Q1 25
$23.4M
$5.3B
Q4 24
$38.3M
$4.8B
Q3 24
$28.5M
$5.2B
Q2 24
$19.2M
$4.6B
Total Debt
ASMB
ASMB
LIN
LIN
Q1 26
$24.7M
Q4 25
$20.7B
Q3 25
$18.6B
Q2 25
$19.7B
Q1 25
$17.6B
Q4 24
$15.3B
Q3 24
$17.5B
Q2 24
$16.9B
Stockholders' Equity
ASMB
ASMB
LIN
LIN
Q1 26
$40.1M
Q4 25
$38.2B
Q3 25
$182.7M
$38.6B
Q2 25
$18.1M
$38.5B
Q1 25
$27.1M
$38.0B
Q4 24
$33.4M
$38.1B
Q3 24
$26.0M
$39.2B
Q2 24
$34.7M
$38.2B
Total Assets
ASMB
ASMB
LIN
LIN
Q1 26
$86.3M
Q4 25
$86.8B
Q3 25
$240.0M
$86.0B
Q2 25
$80.8M
$86.1B
Q1 25
$99.0M
$82.7B
Q4 24
$119.2M
$80.1B
Q3 24
$100.3M
$82.5B
Q2 24
$115.3M
$80.2B
Debt / Equity
ASMB
ASMB
LIN
LIN
Q1 26
0.62×
Q4 25
0.54×
Q3 25
0.48×
Q2 25
0.51×
Q1 25
0.46×
Q4 24
0.40×
Q3 24
0.45×
Q2 24
0.44×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASMB
ASMB
LIN
LIN
Operating Cash FlowLast quarter
$-15.1M
Free Cash FlowOCF − Capex
$-15.2M
$898.0K
FCF MarginFCF / Revenue
-140.7%
10.2%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$4.2B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASMB
ASMB
LIN
LIN
Q1 26
Q4 25
$3.0B
Q3 25
$-15.1M
$2.9B
Q2 25
$-16.8M
$2.2B
Q1 25
$-23.4M
$2.2B
Q4 24
$-51.1M
$2.8B
Q3 24
$-15.2M
$2.7B
Q2 24
$-17.1M
$1.9B
Free Cash Flow
ASMB
ASMB
LIN
LIN
Q1 26
$898.0K
Q4 25
$1.6B
Q3 25
$-15.2M
$1.7B
Q2 25
$954.0M
Q1 25
$891.0M
Q4 24
$-51.1M
$1.6B
Q3 24
$1.7B
Q2 24
$-17.1M
$796.0M
FCF Margin
ASMB
ASMB
LIN
LIN
Q1 26
10.2%
Q4 25
17.9%
Q3 25
-140.7%
19.4%
Q2 25
11.2%
Q1 25
11.0%
Q4 24
-695.2%
18.8%
Q3 24
19.9%
Q2 24
-200.6%
9.6%
Capex Intensity
ASMB
ASMB
LIN
LIN
Q1 26
Q4 25
16.6%
Q3 25
0.4%
14.8%
Q2 25
0.0%
14.8%
Q1 25
0.0%
15.7%
Q4 24
0.4%
15.1%
Q3 24
0.0%
12.8%
Q2 24
0.2%
13.7%
Cash Conversion
ASMB
ASMB
LIN
LIN
Q1 26
Q4 25
1.98×
Q3 25
1.53×
Q2 25
1.25×
Q1 25
1.29×
Q4 24
1.63×
Q3 24
1.76×
Q2 24
1.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons